300199SZSE
🚨 Material Event

Announcement on Approval of Listing Application for Linaclotide API by Wholly-Owned Subsidiary

Hybio Pharmaceutical Co., Ltd.··2 pages

✨ AI Summary

Shenzhen Han's Pharmaceutical Co., Ltd. announces that its wholly-owned subsidiary, Han's Pharmaceutical (Wuhan) Co., Ltd., has received approval from the NMPA for the listing application of Linaclotide API. This marks a significant step for the company's entry into the domestic market for this innovative drug.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300199 Securities Abbreviation: Han's Pharmaceutical Announcement No.: 2026-033

Shenzhen Han's Pharmaceutical Co., Ltd.

Announcement on Approval of Listing Application for Linaclotide API by Wholly-Owned Subsidiary

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

On June 21, 2026, Shenzhen Han's Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received the "Chemical API Listing Application Approval Notice" issued by the National Medical Products Administration from its wholly-owned subsidiary, Han's Pharmaceutical (Wuhan) Co., Ltd. The relevant situation is hereby announced as follows:

I. Basic Drug Information

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.